| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,400 |
4,400 |
4,400 |
4,400 |
| Total Buy Value |
$49,771 |
$49,771 |
$49,771 |
$49,771 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
90,000 |
106,548 |
120,059 |
126,283 |
| Total Sell Value |
$1,251,565 |
$1,496,540 |
$1,589,688 |
$1,658,590 |
| Total People Sold |
1 |
4 |
4 |
4 |
| Total Sell Transactions |
3 |
8 |
13 |
17 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Randolph Sophia |
Chief Medical Officer |
• • – |
2022-12-29 |
4 |
S |
$11.07 |
$17,901 |
D/D |
(1,617) |
270,253 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2022-12-29 |
4 |
S |
$11.07 |
$9,886 |
D/D |
(893) |
53,723 |
|
- |
|
| Pinto Shelly |
VP, Finance and CAO |
• – – |
2022-12-29 |
4 |
S |
$11.07 |
$5,336 |
D/D |
(482) |
62,097 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2022-12-16 |
4 |
OE |
$1.91 |
$189,875 |
D/D |
46,474 |
271,870 |
|
- |
|
| Pinto Shelly |
VP, Finance and CAO |
• – – |
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
62,718 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
74,000 |
542,978 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
225,396 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
55,178 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2022-02-07 |
4 |
OE |
$4.08 |
$67,305 |
D/D |
15,000 |
24,483 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2022-02-03 |
4 |
OE |
$0.99 |
$35,186 |
D/D |
24,154 |
468,978 |
|
- |
|
| Pinto Shelly |
VP, Finance and CAO |
• – – |
2022-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,446 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-12-15 |
4 |
OE |
$0.99 |
$33,788 |
D/D |
23,852 |
188,396 |
|
- |
|
| Lettmann Jason |
Director |
– • • |
2021-12-13 |
4 |
S |
$25.29 |
$8,901,804 |
I/I |
(325,377) |
285,956 |
|
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2021-12-13 |
4 |
S |
$25.29 |
$1,287,431 |
I/I |
(48,390) |
285,956 |
|
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2021-12-10 |
4 |
S |
$30.77 |
$822,719 |
I/I |
(26,274) |
291,758 |
|
- |
|
| Lettmann Jason |
Director |
– • • |
2021-12-10 |
4 |
S |
$30.77 |
$822,719 |
I/I |
(26,274) |
291,758 |
|
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2021-12-09 |
4 |
S |
$31.08 |
$2,463,502 |
I/I |
(76,905) |
294,909 |
|
- |
|
| Lettmann Jason |
Director |
– • • |
2021-12-09 |
4 |
S |
$31.08 |
$2,463,502 |
I/I |
(76,905) |
294,909 |
|
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2021-12-08 |
4 |
S |
$33.23 |
$1,411,871 |
I/I |
(42,458) |
304,131 |
|
- |
|
| Lettmann Jason |
Director |
– • • |
2021-12-08 |
4 |
S |
$33.23 |
$1,411,871 |
I/I |
(42,458) |
304,131 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-11-22 |
4 |
S |
$36.77 |
$547,314 |
D/D |
(14,884) |
164,544 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-11-22 |
4 |
OE |
$4.08 |
$122,400 |
D/D |
30,000 |
179,428 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-10-19 |
4 |
AS |
$54.17 |
$906,714 |
D/D |
(16,700) |
444,598 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-10-18 |
4 |
AS |
$54.33 |
$400,793 |
D/D |
(7,229) |
9,331 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-10-18 |
4 |
OE |
$4.08 |
$29,494 |
D/D |
7,229 |
16,560 |
|
- |
|
101 Records found
|
|
Page 2 of 5 |
|
|
